TSX:APS - Toronto Stock Exchange - CA03835T3091 - Common Stock - Currency: CAD
APTOSE BIOSCIENCES INC
TSX:APS (2/14/2025, 7:00:00 PM)
0.255
-0.03 (-8.93%)
The current stock price of APS.CA is 0.255 CAD. In the past month the price decreased by -15%. In the past year, price decreased by -90.27%.
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility ...
Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial ...
TUS+VEN+AZA triplet has potential as frontline therapy to treat large, mutationally diverse populations of AML
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial ...
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 269.79M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 182.24M | ||
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 161.49M | ||
TH.CA | THERATECHNOLOGIES INC | N/A | 114.49M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 104.81M | ||
ONC.CA | ONCOLYTICS BIOTECH INC | N/A | 88.82M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 27.55 | 83.02M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | 18.33 | 73.96M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 73.25M | ||
MDCX.CA | MEDICUS PHARMA LTD | N/A | 54.25M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 52.45M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 50.37M |
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 35 full-time employees. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
APTOSE BIOSCIENCES INC
251 Consumers Rd Suite 1105
North York ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 35
Company Website: https://aptose.com/
Investor Relations: https://www.aptose.com/investors
Phone: 16474799828
The current stock price of APS.CA is 0.255 CAD.
The exchange symbol of APTOSE BIOSCIENCES INC is APS and it is listed on the Toronto Stock Exchange exchange.
APS.CA stock is listed on the Toronto Stock Exchange exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for APS.CA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of APS.CA.
APS.CA does not pay a dividend.
APS.CA will report earnings on 2025-03-24, after the market close.
APS.CA does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.21).
ChartMill assigns a fundamental rating of 1 / 10 to APS.CA. APS.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months APS.CA reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by 62.55% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -327.57% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to APS.CA. The Buy consensus is the average rating of analysts ratings from 7 analysts.